-
ARWR Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Arrowhead Pharmaceuticals (ARWR)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 102.69 mm | 102.69 mm | 102.69 mm | 102.69 mm | 102.69 mm | 102.69 mm |
Cash burn (monthly) | (no burn) | 683.83 k | 57.60 mm | 51.22 mm | 45.74 mm | 38.57 mm |
Cash used (since last report) | n/a | 2.98 mm | 250.67 mm | 222.90 mm | 199.05 mm | 167.86 mm |
Cash remaining | n/a | 99.71 mm | -147.98 mm | -120.21 mm | -96.37 mm | -65.17 mm |
Runway (months of cash) | n/a | 145.8 | -2.6 | -2.3 | -2.1 | -1.7 |
13F holders | Current |
---|---|
Total holders | 271 |
Opened positions | 36 |
Closed positions | 36 |
Increased positions | 89 |
Reduced positions | 89 |
13F shares | Current |
---|---|
Total value | 1.76 tn |
Total shares | 95.78 mm |
Total puts | 423.10 k |
Total calls | 152.00 k |
Total put/call ratio | 2.8 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 15.84 mm | $306.74 bn |
Vanguard | 12.23 mm | $236.88 bn |
Avoro Capital Advisors | 8.89 mm | $172.18 bn |
STT State Street | 6.35 mm | $123.08 bn |
FMR | 6.07 mm | $117.53 bn |
Slate Path Capital | 4.89 mm | $94.62 bn |
T. Rowe Price Investment Management | 3.57 mm | $69.24 mm |
Geode Capital Management | 2.96 mm | $57.43 bn |
Siren, L.L.C. | 2.46 mm | $47.63 bn |
Ubs Global Asset Management Americas | 2.15 mm | $41.73 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Feb 25 | Ingram Douglas S | Common Stock | Grant | Acquire A | No | No | 20.09 | 38,396 | 771.38 k | 38,396 |
23 Jan 25 | Olukotun Adeoye Y | Common Stock | Sell | Dispose S | No | Yes | 21 | 959 | 20.14 k | 35,781 |
7 Jan 25 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | Yes | 19.69 | 8,000 | 157.52 k | 527,201 |
6 Jan 25 | James C Hamilton | Common Stock | Sell | Dispose S | No | Yes | 20.11 | 10,971 | 220.63 k | 272,122 |
6 Jan 25 | James C Hamilton | Common Stock | Sell | Dispose S | No | Yes | 19.68 | 21,758 | 428.20 k | 283,093 |
6 Jan 25 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | Yes | 20.1 | 9,526 | 191.47 k | 535,201 |
6 Jan 25 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | Yes | 19.69 | 19,658 | 387.07 k | 544,727 |
4 Jan 25 | James C Hamilton | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 304,851 |
4 Jan 25 | Patrick O'Brien | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 564,385 |